Departments of Radiopharmaceutical Cancer Research

Medicinal Radiochemistry

• Small molecule and peptide-based radiotracer
• Preclinical Characterization of Radioconjugates
• Therapeutic Alpha-Emitters
• Multi-targeted Radiotheranostics
• Biological evaluation and modulation of targeted, radiometal-based bioconjugates

Radiopharmaceutical and Chemical Biology

• Radiotracer and Drug Development
• Theranostic Targets and Experimental Models
• Radiopharmacology and Cancer Imaging
• Tissue Remodeling and Inflammation Imaging
• Radiometals and Functional Labeling Chemistry
• Metabolic and Immune Imaging Biomarkers

Positron Emission Tomography

• Quantitative parameters for the evaluation of oncological PET
• AI-based delineation of tumors and reference regions in PET
• AI-based enhancement of image quality and quantification in PET
• Quantitative parameters for the evaluation of functional MRI data (fMRI)

Radioimmunology

• Antibody-based immunotheranostics for tumor therapy and diagnosis
• Adapter CAR-based immunotheranostics for personalized immunotherapy and diagnosis
• Modulation of tumor microenvironment
• Development of immuno- and radiotherapy
• Personalized immunotheranostics for acute myeloid leukemia

Nano-Microsystems for Life Sciences

• Bionanoelectronics
• 3D Bioreactors
• Droplets microfluidics for clinical diagnostics

Experimental Neurooncological Radiopharmacy

• Molecular imaging of the adenosine receptors A_2A and A_2B
• PET Imaging of the Human Cannabinoid Receptors Type 2 (CB2R) in the Brain
• Brain tumour proliferation imaging - Development of PET radioligands for sigma2 receptors
• Development of PET radioligands for imaging of mutant isocitrate dehydrogenase 1 (mIDH1) in brain tumours
• Development of PSMA ligands for the diagnosis and treatment of prostate cancer

Targetry, Target Chemistry and Radiopharmacy

• Production of radioisotopes at the proton accelerator cyclotron TR-Flex by means of (p,X) nuclear reactions.
• Development of new target technology, target preparation processes and processes for the separation and preparation of radionuclides.
• Supply of the Institute for Radiopharmaceutical Cancer Research and external cooperation partners with radionuclides for research and development such as 18F, 11C, 64Cu, 67Cu, 131Ba, 133La, 197(m)Hg, ...
• Providing PET radiopharmaceuticals for daily clinical use (18F-FDG, 18F-FDOPA, 18F-PSMA-1007, 18F-FMISO, 11C-methionine) according to GMP and AMG including quality control.
• GMP-compliant transfer of newly developed radiotracers and manufacturing processes into clinical application.
• Scaling of the processes for the generation of radionuclides and the production of radiopharmaceuticals to industrial scale and knowledge transfer to industrial partners.
• Cooperation with external accelerator facilities to integrate alternative nuclear reactions into the nuclide production process.